TL;DR
Azelaic acid was identified as a skin-relevant molecule in the 1970s by Marcella Nazzaro-Porro’s lab in Rome, studying pigmentation disorders. It entered prescription dermatology in the 1980s and 1990s as Skinoren and Finacea for acne, rosacea, and melasma. Despite strong evidence across all three indications, it stayed a prescription footnote for forty years. The cosmetic mainstream only discovered it in the late 2010s, when independent brands like The Ordinary and Paula’s Choice started featuring lower-percentage versions.
Azelaic acid has, in my view, the most underrated trajectory of any modern skincare ingredient. The evidence has been solid for forty years. The clinical use has been steady in dermatology offices for thirty. The cosmetic shelf only caught up in the last five. There is a reasonable case that no other ingredient has waited as long for the consumer market to notice it.
The molecule itself is unglamorous. A nine-carbon dicarboxylic acid produced naturally by Malassezia furfur, the yeast that lives on most human skin. It is found in wheat and rye in small amounts. It is, biochemically, not exotic. Its therapeutic profile is what made it interesting.
The Rome lab and pityriasis versicolor
The clinical interest in azelaic acid began with Marcella Nazzaro-Porro and Siro Passi at the University of Rome in the 1970s. The team was studying pityriasis versicolor, the skin condition caused by Malassezia overgrowth, and noticed something unusual. Patients with active pityriasis versicolor often had hypopigmented patches in the affected areas. The pigment loss persisted after the yeast was cleared.
Nazzaro-Porro hypothesized that something Malassezia produced was inhibiting melanin synthesis. The team isolated and characterized several dicarboxylic acids from yeast culture media, and azelaic acid was the most active. The 1978 paper in the Journal of Investigative Dermatology demonstrated that topical azelaic acid could produce measurable depigmentation in hyperpigmented skin, with a mechanism that involved selective effects on hyperactive melanocytes while leaving normal pigment-producing cells largely undisturbed.
That selectivity was the breakthrough. Other depigmenting agents at the time (hydroquinone in particular) acted broadly on all melanocytes and produced known long-term safety concerns. Azelaic acid acted preferentially on the abnormal cells. The therapeutic ceiling was lower, but the safety profile was substantially cleaner.
The prescription era
Through the 1980s and 1990s, azelaic acid moved through pharmaceutical development. Schering AG (later Bayer) licensed the molecule and developed Skinoren, a 20 percent cream that received marketing authorization in Europe in the late 1980s for inflammatory acne and pigmentation disorders. The 15 percent gel formulation (Finacea) followed in the 1990s and received FDA approval for rosacea in 2002.
The clinical evidence that accumulated through this period was strong across multiple indications. For acne, azelaic acid produced comparable results to benzoyl peroxide with less irritation. For melasma, it produced comparable results to 4 percent hydroquinone with a cleaner safety profile. For rosacea, it produced one of the few topical interventions with controlled-trial evidence for reducing papules and pustules.
Despite this, azelaic acid remained a prescription-only product in most markets through the 2000s and 2010s. It was widely used in dermatology offices, particularly for rosacea and melasma, but almost invisible in the consumer cosmetic market.
The cosmetic delay
The reason azelaic acid stayed obscure is partly regulatory and partly commercial. The prescription strength (15 to 20 percent) was tied to drug approvals, which meant cosmetic companies could not use those concentrations without classifying their products as drugs. Lower percentages (under 10 percent) were technically permissible in cosmetics but had thinner clinical evidence and a less compelling marketing story.
The commercial issue was that azelaic acid produced visible results slowly and worked on conditions (rosacea, melasma) that were less marketable than wrinkles or acne. The premium skincare industry preferred ingredients with faster visible effects and broader consumer narratives. Azelaic acid had neither.
The shift came in the late 2010s. The Ordinary launched a 10 percent azelaic acid suspension in 2017 at a low price point. Paula’s Choice followed with a 10 percent booster. Several other independent brands released azelaic acid serums in the same window. The category went from invisible to standard within roughly three years, driven mostly by the skincare communities on Reddit and YouTube that had spent years recommending the prescription version off-label.
The contrarian H2: the underused ingredient for rosacea is not a hype ingredient
I notice a pattern in skincare recommendations for rosacea. The internet defaults to expensive moisturizers, calming serums, and various microbiome-marketing products. The clinical evidence for any of those is thin. Azelaic acid, by contrast, has 30 years of controlled-trial evidence specifically for the papulopustular form of rosacea, and it remains the cheapest first-line intervention with that evidence base.
The disconnect makes me wonder whether the skincare market actively avoids unsexy ingredients. Azelaic acid does not have a glamorous origin story (yeast metabolite isolated in a Rome lab studying fungal skin infections). It does not promise glow or radiance. It is messy in formulation because it crystallizes at high percentages and needs careful suspension. The marketing department’s job is harder.
For rosacea-prone skin specifically, the question I would ask before any expensive serum is whether azelaic acid 15 percent (prescription) or 10 percent (cosmetic) has been tried for at least 12 weeks. Most rosacea routines I have audited have not, and the alternatives are usually more expensive with thinner evidence.
The real numbers
The 2003 Cochrane review on topical treatments for melasma, updated in subsequent revisions, compared azelaic acid 20 percent to hydroquinone 4 percent across multiple trials and concluded that the two were comparable in efficacy for moderate melasma, with azelaic acid showing a cleaner long-term safety profile. The 2004 study by Elewski and colleagues in JAAD on azelaic acid 15 percent gel for rosacea enrolled 664 patients in two 12-week trials and reported a 58 percent reduction in inflammatory lesions compared with vehicle, with statistically significant improvement in erythema.
A 2017 review in JAMA Dermatology by van Zuuren and colleagues placed azelaic acid in the highest evidence tier for papulopustular rosacea, alongside ivermectin and metronidazole, and ahead of most other commonly recommended interventions.
What this means for your routine
The history points to a few practical anchors. For rosacea-prone skin, azelaic acid (prescription 15 percent or cosmetic 10 percent) is one of the highest-evidence interventions in the topical space. For post-inflammatory hyperpigmentation, especially on skin of color where hydroquinone safety is a concern, azelaic acid is a defensible alternative. For inflammatory acne, it pairs well with retinoids and reduces some of the irritation those produce.
Application is straightforward. Start every other day if your skin is reactive. Build to daily. Pair with a barrier-supportive moisturizer. Pair with SPF. The expected timeline is 8 to 12 weeks for visible effects on pigmentation and 4 to 6 weeks for inflammatory lesions.
For the broader thinking, see the rosacea routine guide, the melasma treatment primer, and the azelaic acid versus niacinamide comparison.
FAQ
Who discovered azelaic acid for skin use? Marcella Nazzaro-Porro and Siro Passi at the University of Rome, in a 1978 paper in the Journal of Investigative Dermatology. The work originated from observing hypopigmentation in pityriasis versicolor patients.
Why was azelaic acid prescription-only for so long? The therapeutic concentrations (15 to 20 percent) were tied to drug approvals, which restricted cosmetic use. Lower percentages were technically allowed in cosmetics but had thinner marketing appeal and weaker evidence.
Is the 10 percent cosmetic version as good as the 20 percent prescription? Not quite. The dose-response curve is meaningful in this percentage range. The 10 percent versions are useful and well-tolerated, but the higher prescription strengths produce stronger effects on resistant pigmentation and rosacea.
Can azelaic acid be combined with retinoids? Yes. The two combine well in practice and are often used together for acne. Introduce them one at a time to assess tolerance.
Why does azelaic acid feel like sand in some formulations? Because it crystallizes at high percentages and suspension is technically difficult. Better-formulated products (Finacea gel, for example) have smoother textures; lower-cost cosmetic suspensions sometimes do not.
Tag hub: More on azelaic acid for rosacea, melasma, and acne
Sources
Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. Journal of Investigative Dermatology 1978. Elewski BE et al. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. JAAD 2003. van Zuuren EJ et al. Interventions for rosacea. JAMA Dermatology 2017. Cochrane Review of Interventions for Melasma 2010.